Health/Medical Writers / Business Editors
RENO, Nev.--(BUSINESS WIRE)--LBTT--
Jim Holmes, CEO Lifeline Biotechnologies, Inc.
(OTC:LBTT) today announced that its MastaScope(TM) System, for the
early detection of breast abnormalities that can become cancerous, was
introduced June 28, 2004 and demonstrated at the National Cancer
Institute (NCI) in Cairo, Egypt. As reported by Carlo Micheletti,
Lifeline's Director of International Marketing and Sales, "Attending
the demonstration were approximately 100 oncology surgeons, breast
cancer specialists and radiologists from Cairo and surrounding areas,
three from Saudi Arabia and two from Turkey. The program was simulcast
via TV to several other hospitals throughout Egypt."
Dr. Kefah Mokbel, Lifeline's senior clinical consultant, began the
presentation with information about the latest advances in breast
cancer, followed by slides on Mammary Ductoscopy. The program
continued with two live cases performed in a side room of the
auditorium. These patients were referred to the NCI for further
examination and prognosis by their primary care physicians. The
patients exhibited breast abnormalities that include pathological
nipple discharge (PND), an early warning sign of breast cancer. The
procedure, assisted by medical personnel of the NCI, was projected
onto the theater screen for the audience's viewing.
Mr. Micheletti said, "The response was very enthusiastic about the
procedure, Dr. Mokbel's skills, and the usefulness of the
MastaScope(TM). The patients were superb and exhibited little to no
discomfort during the procedure. The Saudi Arabian physicians already
have advised New Horizon, Lifeline's distributor for Egyptian and
other Middle Eastern countries, of their intent to purchase a system.
The Turkish doctor, chief breast cancer specialist at the state
hospital in Antalya, Turkey, also expressed great interest in
purchasing a system. Several physicians at the NCI, including the
chief radiologist, are talking to New Horizon about purchasing a
Micheletti went on to say, "The exposure from this event, first of
its kind in the region, is expected to be the catapult for the Mammary
Ductoscopy procedures throughout the Middle East and should position
Lifeline and the MastaScope(TM) System as the leader in the early
detection of breast cancer pathologies."
Breast cancer awareness and the methods that can best be utilized
in its detection and treatment, as well as prevention have become a
major focus of Egypt's First Lady, Mrs. Mobaurek. She has been
spearheading an intense educational campaign to increase people's
awareness of the fight against breast cancer and the best methods
available for its early detection.
Lifeline is a company that is developing products that assist in
the early detection of women's cancers. The first of those products is
the Mastascope(TM). Two other products are in the process of
development, the First Warning System(TM) to assist in the early
detection of breast cancer and the OvaScope to assist in the early
detection of ovarian cancer. Lifeline, through its orthopedic
division, is the exclusive distributor for the Arthronet shaver blades
in North America and the Inion hexalon bioabsorbable screws in the US
Lifeline's website address: www.lbti.com
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
particular, when used in the preceding discussion, the words
"believe," "expects," "projects," "forecasts," "intends," "will,"
"anticipated," or "may," and similar conditional expressions are
intended to identify forward-looking statements within the meaning of
the Act and subject to the safe harbor created by the Act.
KEYWORD: INTERNATIONAL AFRICA/MIDDLE EAST NEVADA
INDUSTRY KEYWORD: MEDICAL MEDICAL PRODUCT
SOURCE: Lifeline Biotechnologies, Inc.
Jim Holmes, 775-324-1933
Jim Stock, 866-242-2405 (Investor Relations)
Due Da Due......But Be Quick About It!!!!!